YaSheng Group

YaSheng Group

HERB
YaSheng GroupUS flagOther OTC
0.02
USD
-0.01
- -
3.61MMarket Cap
YaSheng Group
HERB
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
TTM
FRC
3.49
3.66
3.89
4.23
4.75
4.77
5.48
6.12
6.4
6.52
6.53
- -
6.03
Revenue per Share
0.32
0.4
0.43
0.46
0.49
0.5
0.63
0.74
0.82
0.88
0.88
- -
0.72
Basic EPS, GAAP
0.24
-0.18
-0.15
-0.49
-0.46
0.3
0.15
0.05
0.08
0.05
0.04
- -
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.53
6.93
7.36
7.82
8.31
8.8
9.43
10.16
10.98
11.86
12.74
- -
1.73
Book Value per Share
2.11
2.58
2.57
3.17
3.75
4.17
4.95
5.85
6.82
7.9
8.54
- -
0.72
Tangible Book Value per Share
155
155
155
155
155
155
155
155
155
155
155
- -
156
Basic Weighted Avg Shares
542
567
603
656
736
740
849
949
993
1,011
1,012
939
939
Sales/Revenue/Turnover
9.99
11.18
11.18
11
10.43
10.58
11.66
12.18
12.75
13.52
13.53
12.05
12.05
Operating Margin (%)
6
11
8
8
9
9
9
9
11
13
13
14
14
Depreciation Expense
49
62
66
71
76
77
97
114
126
136
137
112
112
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
9.14
10.91
11.01
10.88
10.32
10.47
11.47
12.03
12.73
13.5
13.53
11.92
11.92
Profit Margin (%)
-1
3
10
26
28
72
125
174
293
394
433
118
118
Working Capital
60
70
103
109
81
55
2
2
28
25
21
46
46
LT Debt
1,013
1,101
1,204
1,363
1,527
1,605
1,753
1,959
2,091
2,282
2,422
213
213
Total Equity
- -
5.29
5.14
4.96
4.81
4.68
5.72
6.16
6.17
6.16
5.75
8.37
8.37
Return on Invested Capital (%)
- -
5.44
5.42
5.48
5.61
5.57
6.8
7.54
7.63
7.59
7.09
9.69
9.69
Return on Capital (%)
- -
5.93
5.99
6.06
6.08
5.84
6.9
7.51
7.71
7.71
7.18
9.97
9.97
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'15
Sep'15
Dec'15
ST Debt
8
7
- -
LT Borrowings
- -
- -
46
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
155
157
157
Market Capitalization
115
82
79

Working Capital

FRC

in mil. unless spec.
Jun'15
Sep'15
Dec'15
Total Current Assets
498
523
118
Cash, Cash Equivalents & STI
12
11
1
Accounts Receivable, Net
125
124
1
Inventories
357
384
1
Total Current Liabilities
34
34
- -
Payables & Accruals
26
26
- -
ST Debt
8
7
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.85%
-11.5%
-91.22%
Free Cash Flow
-23.84%
-45.02%
-153.68%
Net Income, GAAP
6.68%
3.58%
-18.3%
Sales/Revenue/Turnover
5.36%
2.21%
-7.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
205
193
290
323
1,011
2014
209
226
273
304
1,012
2015
210
230
270
229
939

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
0.13
0.14
0.28
- -
0.88
2014
0.14
0.16
0.28
- -
0.88
2015
0.14
0.17
0.26
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Business
Humanoid Inc (OTC: HERB), formerly YaSheng Group, operates as a U.S.-based holding company with business activities spanning the United States, China, and the Philippines across four primary segments including agriculture and fisheries; biotechnology; blockchain and IoT; and mining. The company develops, processes, markets, and distributes a broad range of agricultural products such as betel nut, coconut, coffee, banana, sugarcane, golden cardaba, mango, wolfberry, hemp, herbs, field crops, vegetables, fruits, dried fruit packages, garlic extract gels, feed materials, flowers, special crops, seeds, poultry, potato, hops extracts, pellet and compressed hops, and Chinese traditional medicine (TCM) herbs; it also manufactures and supplies biotechnology products encompassing standardized herbal extracts, botanical herb powders, herbal tea bag cuts, traditional Chinese medicals and extracts, nutrition and health care items derived from supercritical carbon dioxide extraction processes, ginkgo, songaricum, and hemp seeds, with research and development facilities focused on natural ingredients, phytochemistry, analytical testing, biological research, microbiology, and medical formulations. Products export to 15 countries worldwide through 2,875 cooperative regions and distribution agents, targeting food processors, supermarkets, wholesale stores, direct customers, researchers in academia and industry, and international markets emphasizing organic and green food certifications including ISO, HACCP, Halal, and Kosher standards. Founded in 1998 and headquartered at 710 Lakeway Drive, Suite 200, Sunnyvale, California 94085, the company maintains operations rooted in northwest China agro bases, Philippine joint ventures such as Yongsheng Environmental Technology for betel nut processing and RMT1-N for organic farming of medicinal plants like akapulko, ampalaya, bawang, bayabas, lagundi, niyog-niyogan, sambong, tsaang gubat, ulasimang bato, pansit-pansitan, and yerba buena, and blockchain initiatives including the Betel Nut Chain (BNC) digital platform for anti-counterfeiting traceability, supply chain finance, futures trading, and asset tokenization. Recent developments encompass a name change from YaSheng Group to Humanoid Inc in April 2024 in anticipation of material events; a strategic collaboration announced in August 2024 with Kronos Advanced Technologies Inc (OTC: KNOS) to develop and patent a small nuclear battery utilizing Nickel-63 beta decay for up to 50-year lifespan applications in remote sensing, space exploration, medical devices, and military sectors, with Yasheng handling China patent filing and Kronos managing North America; expansion into healthy betel nut production equipment via Yongsheng with 22 technical patents for low-temperature fumigation reducing carcinogens; and blockchain integration for the global betel nut industry to enhance asset circulation and rural revitalization in Hainan Free Trade Port.

Company News

APIChatGPT
  • Herbal Dispatch Announces Vesting of RSUs and Satisfaction of Certain Outstanding Fees

  • Herbal Dispatch Provides Update on Domestic Retail Operations and Proprietary Brand Expansion

  • Herbal Dispatch Inc. Appoints Jason Spatafora as Strategic Advisor

  • Herbal Dispatch Reports First Quarter 2026 Results and Provides Business Update

  • Herbal Dispatch Secures EU-GMP Processing Partnership to Accelerate German and European Export Growth

  • Herbal Dispatch Reports Accelerating Veteran Customer Growth and Expansion of Insurance-Focused Service Channel

  • Herbal Dispatch Provides Market Update on Launch of First Edible Brand: Chomp Edibles

  • Herbal Dispatch Reports Q4 2025 Gross Sales of $6.2 Million, Achieves Positive Adjusted EBITDA, and Reports Full Year Gross Sales of $16.5 Million

  • Herbal Dispatch Welcomes the Honourable Herb Dhaliwal as Full-Time Chairman

  • YaSheng Group (OTCMKTS:HERB) Short Interest Up 60,020.0% in January

  • YaSheng Group (OTCMKTS:HERB) Short Interest Up 60,020.0% in January

  • Herbal Dispatch Announces Extension of Convertible Debentures

  • Herbal Dispatch Approved for Listing on the OTCQB

  • Herbal Dispatch Announces 298kg Export Destined for German Market

  • Third Consecutive Year of Double Digit Growth - Herbal Dispatch Recaps Key Milestones for 2025

  • Herbal Dispatch Unveils Strategic Business Plan for 2026 to Drive Sustainable Growth and Enhance Shareholder Value

  • Herbal Dispatch Provides Update on Sold Out Product Launch

  • Herbal Dispatch Announces Record-Breaking Month of $4.1M in Sales for October 2025

  • Herbal Dispatch Brings on Industry Veteran as Strategic Advisor

  • Herbal Dispatch Drives Sustained Growth and Retail Support Amid BCGEU Strike, Boosting Shareholder Value